Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:

NCT ID: NCT04931459 Not yet recruiting - Alzheimer Disease Clinical Trials

A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD

Start date: June 2021
Phase: Phase 1
Study type: Interventional

This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when administered to participants diagnosed with Mild Cognitive Impairment (MCI) or Mild Dementia due to Alzheimer's disease (AD).

NCT ID: NCT04928976 Recruiting - Alzheimer Disease Clinical Trials

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping

AMYPRED-US
Start date: January 22, 2021
Phase:
Study type: Observational [Patient Registry]

The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, as measured by the AUC of the receiver operating characteristic (ROC) curve of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) Arms. Secondary objectives include (1) evaluating whether similar algorithms can detect amyloid-specific cognitive impairment in the cognitively normal (CN) and MCI Arms respectively, as measured on binary classifier performance; (2) whether they can detect MCI, as measured on binary classifier performance (AUC, sensitivity, specificity, Cohen's kappa), and the agreement between the PACC5 composite and the corresponding regression model predicting it in all Arms pooled (Wilcoxon signed-rank test, CIA); (3) evaluating variables that can impact performance of such algorithms of covariates from the speaker (age, gender, education level) and environment (measures of acoustic quality).

NCT ID: NCT04928690 Not yet recruiting - Alzheimer Disease Clinical Trials

Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping

EARS
Start date: June 20, 2021
Phase:
Study type: Observational [Patient Registry]

The S22 study investigates, in a cross-sectional study, the ability of algorithms that analyse acoustic and linguistic patterns of spoken language to predict the presence of amyloid positivity in early stage Alzheimer's disease, specifically in Mild Cognitive Impairment (MCI) and cognitively normal (CN) cohorts; and whether similar algorithms can predict cognitive functioning, in classifying MCI vs CN.

NCT ID: NCT04926272 Recruiting - Alzheimer's Disease Clinical Trials

Amyloid-beta PET Imaging With 18F-92 in Alzheimer's Disease

Start date: June 2021
Phase: Early Phase 1
Study type: Interventional

Alzheimer's disease is a neurodegenerative disease. Numerous studies have reported that β-amyloid (Aβ) is an important marker for the diagnosis of AD. 18F-92 molecular probe is a novel molecularly targeted imaging agent, which can rapidly penetrate the blood-brain barrier and has high affinity and selectivity for Aβ protein. In this study, 18F-92 PET/CT was used to monitor the regional distribution and the degree of deposition in patients with Alzheimer's disease, and compared with clinical symptoms (neuropsychometry) to evaluate its application value in the diagnosis of AD.

NCT ID: NCT04924361 Recruiting - Dementia Clinical Trials

Exploring Biomarkers in Age Stratified PUMCH Dementia Cohort

Start date: December 1, 2020
Phase:
Study type: Observational

Biomarkers are important for early and precise diagnosis of dementia. However, the causes of dementia in different age are different. We designed an age stratified dementia cohort and tried to explore biomarkers of different groups of dementia, incorporating neuropsychology, multi-model neuroimaging, metabolics and proteomics based fluid biomarkers as well as genetic biomarkers. Autopsy after clinical follow up help to verify the biomarkers.

NCT ID: NCT04920786 Recruiting - Alzheimer Disease Clinical Trials

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

TB006SAD
Start date: June 1, 2021
Phase: Phase 1
Study type: Interventional

This is a single dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TB006, a monoclonal antibody that will be studied as a disease modifying treatment for Alzheimer's disease.

NCT ID: NCT04919005 Completed - Alzheimer Disease Clinical Trials

Virtual Environment to Aid Cognitive Stimulation of Elderly People With Early Alzheimer's

Start date: July 1, 2016
Phase: N/A
Study type: Interventional

This research was carried out with the objective of verifying the possibility of intervention through cognitive training protocols to assist in the stimulation of neurons and to delay the degradation resulting from Alzheimer's disease in its initial phase. The specific objective of this research was to develop and validate a virtual environment of games (called SorrisoTur) that allows the intervention of cognitive training.

NCT ID: NCT04916964 Recruiting - Clinical trials for Alzheimer Disease, Early Onset

Adapted Home-based Exercise Program "T&E" (Test-and-Exercise) in Persons With Alzheimer's Disease (HOPE Trial)

HOPE
Start date: June 30, 2021
Phase: N/A
Study type: Interventional

The aim of this exploratory pilot study is to assess the feasibility and effectiveness of the adapted T&E home-based exercise program on the basic functional mobility and executive functions in persons with mild or probable Alzheimer's Disease.

NCT ID: NCT04913818 Recruiting - Mild Dementia Clinical Trials

Effects of the Buddy-Up Dyadic Physical Activity Program on Health Outcomes of Care Dyads of Dementia: A Pilot Study

BUDPA
Start date: November 1, 2020
Phase: N/A
Study type: Interventional

This project seeks to develop a novel dyadic intervention (titled as Buddy-Up Dyadic Physical Activity; BUDPA), using exercise as the common treatment component to improve the cognitive outcomes of persons with dementia and manage the stress-related symptoms of their family caregivers.

NCT ID: NCT04913454 Not yet recruiting - Alzheimer Disease Clinical Trials

CLearing Alzheimer's Disease Molecular Pathology Without Medications

CLAMP
Start date: August 1, 2021
Phase: N/A
Study type: Interventional

According to the most popular pathophysiological models of Alzheimer's disease, the amyloid hypothesis, amyloid deposition is the causative event triggering a chain of other downstream events which finally lead to Alzheimer's disease and dementia. In mouse models of Alzheimer's disease, 40 Hz multi-sensory (auditory and visual) stimulation was able to reduce the number and size of amyloid plaques throughout cortex and improve cognitive performance. The primary objective of this study is to assess whether an intervention consisting of 40 Hz multi-sensory (auditory and visual) stimulation is able to reduce the amyloid load in non-demented amyloid-positive individuals. As secondary objectives, the investigators will assess whether such intervention is able to: - improve the brain electrical activity, - improve or slow down the worsening of Alzheimer's blood-based biomarkers, - improve or slow down the worsening of cognition.